Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014:2014:580171.
doi: 10.1155/2014/580171. Epub 2014 Jul 15.

Pharmaceutical options for triggering of final oocyte maturation in ART

Juan Carlos Castillo  1 , Peter Humaidan  2 , Rafael Bernabéu  1
Affiliations
Review

Pharmaceutical options for triggering of final oocyte maturation in ART

Juan Carlos Castillo et al. Biomed Res Int. 2014.

Abstract

Since the pioneering days of in vitro fertilization, hCG has been the gold standard to induce final follicular maturation. We herein reviewed different pharmaceutical options for triggering of final oocyte maturation in ART. The new upcoming agent seems to be GnRHa with its potential advantages over hCG trigger. GnRHa triggering elicits a surge of gonadotropins resembling the natural midcycle surge of gonadotropins, without the prolonged action of hCG, resulting in the retrieval of more mature oocytes and a significant reduction in or elimination of OHSS as compared to hCG triggering. The induction of final follicular maturation using GnRHa represents a paradigm shift in the ovulation triggering concept in ART and, thus, a way to develop a safer IVF procedure. Kisspeptins are key central regulators of the neuroendocrine mechanisms of human reproduction, who have been shown to effectively elicit an LH surge and to induce final oocyte maturation in IVF cycles. This new trigger concept may, therefore, offer a completely new, "natural" pharmacological option for ovulation induction. Whether kisspeptins will be the future agent to trigger ovulation remains to be further explored.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Differences in LH surge after GnRH-agonist triggering when compared with a natural cycle.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kessler MJ, Reddy MS, Shah RH, Bahl OP. Structures of N-glycosidic carbohydrate units of human chorionic gonadotropin. The Journal of Biological Chemistry. 1979;254(16):7901–7908. - PubMed
    1. Yen SS, Llerena O, Little B, Pearson OH. Disappearance rates of endogenous luteinizing hormone and chorionic gonadotropin in man. The Journal of Clinical Endocrinology and Metabolism. 1968;28(12):1763–1767. - PubMed
    1. Damewood MD, Shen W, Zacur HA, Schlaff WD, Rock JA, Wallach EE. Disappearance of exogenously administered human chorionic gonadotropin. Fertility and Sterility. 1989;52(3):398–400. - PubMed
    1. Nakano R, Mizuno T, Kotsuji F, Katayama K, Wshio M, Tojo S. ‘Triggering’ of ovulation after infusion of synthetic luteinizing hormone releasing factor (LRF) Acta Obstetricia et Gynecologica Scandinavica. 1973;52(3):269–272. - PubMed
    1. Diedrich K, Diedrich C, Santos E, et al. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Human Reproduction. 1994;9(5):788–791. - PubMed

MeSH terms

Substances